



Investor Presentation

Cowen Annual Health Care Conference
March 9, 2022

Søren Tulstrup
CEO



...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Successful track record...
Strong momentum...
Promising future...

A validated technology

VALIDATION ACROSS THREE AREAS

- ✓ Approval in kidney transplantations
- ✓ Proof of concept in autoimmune diseases
- ✓ Partnerships to explore gene therapy

Idefirix® is our first approved drug in Europe*

EUROPE KIDNEY TRANSPLANTS

For highly sensitized patients in Europe

Broad pipeline in transplantation and autoimmunity

PROGRAMS IN CLINICAL DEVELOPMENT

US kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

Established a high-performance organization

NEW COMPETENCIES ADDED

133 employees December 2021
(~3x in 3 years)

Highly qualified team with 20 years on average in life science

Purpose driven culture

With recent capital injection Hansa is financed into 2023

FINANCIALS

SEK 889m in Cash (USD ~98m)
December 2021

Created shareholder value and diversified our ownership base

MARKET CAPITALISATION (USD): ~0.3bn

Listed on Nasdaq Stockholm
18,000 shareholders

Foreign ownership make up ~40% through leading international life science specialist funds



*Idefirix approved in EEA under conditional approval for kidney transplantation

**Actual patient has given consent to provide images

Many milestones achieved during the last 15 months

TLV

TANDVÅRDS- OCH
LÄKEMEDELSFORMÄNSVERKET

Healthcare Technology Assessment published by Swedish "TLV", with a favorable conclusion for using Idefix® in highly sensitized patients incompatible with a deceased donor

idefix
(imlifidase)

Hansa Biopharma records first commercial sale of Idefix®



First national market access agreement achieved for Idefix® in Sweden and Finland (hospital basis)


Full national reimbursement agreement achieved for Idefix® in the Netherlands



First patient enrolled in the U.S. pivotal randomized controlled study "ConfideS" in highly sensitized kidney transplant patients

MEDISON
Delivering Innovative Healthcare

New multiregional commercialization partnership with Medison Pharma for imlifidase in kidney transplant in Central Eastern Europe and Israel


Pricing and reimbursement obtained in France on an early access basis

2021

January

February

March

April

May

June

July

August

September

October

November

December

2022

January

February

March

Hansa Biopharma enters pre-clinical research collaboration with argenx BV to explore potential combination therapies with imlifidase and efgartigimod

argenx

Positive 3-year follow-up data published in American Journal of Transplantation demonstrating graft survival of 84% after imlifidase treatment and transplantation



Hansa Biopharma AB certified as a Great Place to Work® for second consecutive year



Market access agreement achieved in Greece on a hospital basis



Agreement with AskBio to evaluate feasibility of imlifidase ahead of gene therapy in Pompe disease



HANSA
BIOPHARMA

Imlifidase

A novel approach to eliminate pathogenic IgG


Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection




A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')₂ fragment and one homo-dimeric Fc-fragment




Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Potential indication universe




*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.

***) In the US a new study has commenced targeting a BLA filing by H1 2024

Our Business model

Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications



Idefirix® (imlifidase) has received conditional approval in the European Union

Low
complexity
transplants

Higher
complexity
transplants

~70% of patients^{1,2}

15-20% of patients^{1,2}

10-15% of patients^{1,2}

Non or less sensitized
(cPRA < 20%)

Moderately sensitized
(20% < cPRA < 80%)

Highly sensitized
(cPRA > 80%)

Highly sensitized patients that are likely to be transplanted with a compatible donor

Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients

Potential patients

idefirix®
imlifidase

Actual patient has given consent to provide images

¹ EDQM. (2020). International figures on donation and Transplantation 2019


² SRTR Database and individual assessments of allocation systems

The kidney transplantation landscape in Europe and the U.S.


Up to 15% of patients waiting for a new kidney are highly sensitized

European transplantation rates were negatively affected by COVID-19

Breakdown of the kidney transplant waitlist in U.S. and EU




~50,000 transplants done annually in the U.S. and Europe




Our center focused and sequenced launch process ("S"-shaped launch curve) will help build the foundation for Idefix® to become a new Standard of Care in transplantation

Idefix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers



Market access processes ongoing in 14 countries (incl. EU4+UK ~15,000 annual kidney transplants¹)

Pricing and reimbursement obtained in France (early access), Sweden, Netherlands as well as Finland and Greece on a hospital basis; 10 clinics qualified as clinically ready



¹Annual kidney transplantations 2019 (pre-Corona)

^{*}Transplantation data is from Global Observatory on Donation and Transplantation, 2019

^{**}Pricing & reimbursement obtained in France on an early access basis

U.S. ConfideS study: First patient enrolled Dec'21; BLA submission expected H1 2024

U.S. trial design

64 highly sensitized kidney patients with the highest unmet medical need

- Patients with a cPRA score of $\geq 99.9\%$ will be enrolled
- First patients enrolled at Columbia University, NYC

1:1 Randomization

- When a donor organ becomes available and a positive crossmatch with the intended recipient indicates that the organ is not compatible, the patient will be randomized to either imlifidase or to a control arm, where patients either remain waitlisted for a match or receive experimental desensitization treatment*

Primary endpoint

- Mean estimated glomerular filtration rate (eGFR) “kidney function” at 12 months.
- For randomized patients who do not undergo transplantation, lose their graft or die before 12 months, eGFR will be set to zero, consistent with kidney failure


Secondary endpoint

- Patient survival at 12 months

12-15 leading transplantation centers in the U.S. will be engaged in the study




- Robert A. Montgomery, M.D. Professor of Surgery and Director, NYU Langone Transplant Institute, NYC is appointed to be the principal investigator
- Five clinics are open for recruitment as of February 2, 2022

Timeline



*Experimental desensitization treatment can include any combination of plasma exchange (PLEX), intravenous IVIg, anti-CD20 antibody, and eculizumab. Link to the full protocol at [ClinicalTrials.gov](https://clinicaltrials.gov)

Broad clinical pipeline in transplantation and auto-immune diseases

Candidate/ Program	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
	EU: Kidney transplantation in highly sensitized patients ^{1,2}							EU: Additional agreements around reimbursement from H2'21
	US: Kidney transplantation in highly sensitized patients ^{1,2}							Completion of enrollment (64 patients) H2'22
	Anti-GBM antibody disease ³							Pivotal Phase 3 study expected to commence in 2022 (50 patients)
Imlifidase	Antibody mediated kidney transplant rejection (AMR)							Completion of enrollment (30 patients) H1 2022
	Guillain-Barré syndrome (GBS)							Timeline guidance under review
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)							Preclinical phase
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology							Completion of GLP toxicology studies in 2022
EnzE	Cancer immunotherapy							Research phase

¹ Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)

² Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)

³ Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

 Completed

 Ongoing

 Planned

 Conditional approval based on Phase 2 data

Our unique antibody cleaving enzyme technology may have relevance across a range of indications


Targeting rare IgG mediated diseases

Anti-GBM paves the way for development in other autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

IgG-cleaving enzymes to enable or even potentiate cancer therapy

- Allogenic stem cell (bone marrow) transplantation (HSCT)
- Enzyme-based antibody Enhancement (EnzE)



Expanding our commercial franchises

- Regulatory approval (conditional)
- Clinical development
- Partnership (preclinical development)
- Preclinical development

Shaping a new standard for desensitization will help enable new indications in transplantations

- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

Exploring opportunities in gene therapy

- Encouraging preclinical data published in Nature
- Partnership with Sarepta
- Wide indication landscape beyond

Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease

Feasibility program to evaluate imlifidase as pre-treatment ahead of gene therapy in Pompe disease for patients with pre-existing neutralizing antibodies (NAbs) to adeno-associated virus (AAV)



Hansa's key resources and deliverables

- Imlifidase validated with positive clinical efficacy and safety data as well as European approval
- Significant know-how around antibody cleaving enzymes
- Clear path to U.S. approval (kidney transplant)
- Hansa supplies material and provides additional support




Fully owned subsidiary of Bayer AG


AskBio's key resources and deliverables

- Early innovator in the Gene Therapy space with AAV platform and ongoing clinical stage Pompe disease program
- Conducts pre-clinical and clinical trials according to agreed plan

Current agreement scoped around a feasibility program which covers preclinical work and a Phase 1/2 study




Exclusive option for AskBio to negotiate a potential full development and commercialization agreement



Upcoming milestones

Milestones subject to potential COVID-19 impact



Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

*GBS: Given the current difficulty of predicting enrollment due to the direct and indirect effects of the persistent and even escalating pandemic, Hansa expects to update its guidance for completion of enrollment in GBS in April 2022



HANSA

BIOPHARMA

Corporate Contacts

Investor Relations and
Corporate Communications

Visit our web site
www.hansabiopharma.com



Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com



Katja Margell

Head of Corporate Communications

Mobile: +46 (0) 768-198 326

Email: katja.margell@hansabiopharma.com

Calendar and events

Mar 15, 2022

Mar 23, 2022

Mar 31, 2022

April 7, 2022

April 11-14, 2022

April 21, 2022

April 21, 2022

April 27, 2022

May 16, 2022

June 16, 2022

July 21, 2022

Aug 8-11, 2022

Sept 7-8, 2022

Oct 20, 2022

Carnegie Healthcare Seminar 2022, Stockholm

Swiss Nordic Midcap Conference (virtual)

Redeye Investor Forum, Malmö

Annual Report 2021

Needham Virtual Healthcare Conference, 2022

Interim Report for January-March 2022

Kempen Life Sciences Conference 2022, Amsterdam

Redeye Orphan Drugs 2022, Stockholm

Copenhagen Midcap Event , Copenhagen

Annual General Meeting 2022

Half year 2022 report

Canaccord Annual Growth Conference 2022

CITI Annual Biopharma Conference 2022

Interim Report for January-September 2022